May 13, 2021 -- PerkinElmer has entered into an agreement to acquire life sciences instrumentation firm Nexcelom Bioscience for $260 million, a deal that is expected to be completed in the second quarter of 2021.
Nexcelom is a provider of automated cell counting instruments, image cytometry workstations, assays, and a variety of cell reagents and consumables. It also provides fit-for-purpose cell counting method selection and development services to support cell and gene and immuno-oncology therapies, virology drugs, and vaccine development.
Nexcelom's technology portfolio will complement PerkinElmer's existing capabilities, including high content, in vivo, and cell painting screening technologies; immunoassays; CRISPR, RNA interference (RNAi), and DNA tools and custom cell lines; cell plate readers and advanced automation; and microfluidics and analytical platforms, the firms said.
Copyright © 2021 scienceboard.net